Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company's Phase III ExteNET Trial of neratinib for early stage...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875...
Investors in Puma Biotechnology Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BERY, DLTH, DNB, ETSY, LND, MOS Downgrades: CIZN, CVV, FCX, LIND, OAS, PACW, PTVCB, STN, SYF, WAFD Initiations: CSSE, PBYI, PVG, SMPL, TRMT Read on to get TheStreet Quant Ratings' detailed report:
Investors in Puma Biotechnology Inc saw new options begin trading today, for the December 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new December 28th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology Inc , where a total volume of 7,141 contracts has been traded thus far today, a contract volume which is representative of approximately 714,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 82.3% of PBYI's average daily trading volume over the past month, of 867,945 shares.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018.
Investors in Puma Biotechnology Inc saw new options become available this week, for the December 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new December 7th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 9, 2018, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 18,750...
Puma Biotechnology, Inc. (Nasdaq: PBYI) has been advised that its licensing partner CANbridge Pharmaceutical Inc received confirmation that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for NERLYNX®...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125...
Puma Biotechnology, Inc. (Nasdaq:PBYI) announced that the European Commission (EC), has granted marketing authorisation for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive...
Investors in Puma Biotechnology Inc saw new options become available today, for the October 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new October 5th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018.
Investors in Puma Biotechnology Inc saw new options begin trading today, for the September 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new September 28th contracts and identified one put and one call contract of particular interest.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for the medicinal product NERLYNX® (neratinib) for the extended adjuvant treatment of adult...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that on June 28, 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for the medicinal product NERLYNX® (neratinib) for the...
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive trend vote recommending the approval of the Marketing Authorisation Application...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1...
